Optimality, Future and Terminal Costs: Comment on “Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran”

被引：0
|
作者：
Noga Gershon
Yakir Berchenko
机构：
[1] Ben-Gurion University of the Negev,Department of Industrial Engineering and Management
来源：
PharmacoEconomics | 2018年 / 36卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：383 / 384
页数：1
相关论文
共 50 条
  • [11] Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer
    Haq, Bushra
    Geyer, Charles E.
    WOMENS HEALTH, 2009, 5 (02) : 135 - 147
  • [12] WHAT IS AN EFFICIENT AND AFFORDABLE TRASTUZUMAB THERAPY IN A MIDDLE-INCOME COUNTRY? - ADJUVANT THERAPY WITH TRASTUZUMAB IN MANAGEMENT OF EARLY HER2-POSITIVE BREAST CANCER IN IRAN
    Ansaripour, A.
    Uyl-de Groot, C.
    Redekop, W. K.
    VALUE IN HEALTH, 2016, 19 (07) : A721 - A721
  • [13] Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'
    Ansaripour, Amir
    Uyl-de Groot, Carin A.
    Redekop, W. Ken
    PHARMACOECONOMICS, 2018, 36 (03) : 381 - 382
  • [14] Response to ‘Comment on ‘‘Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy”’
    Amir Ansaripour
    Carin A. Uyl-de Groot
    W. Ken Redekop
    PharmacoEconomics, 2018, 36 : 381 - 382
  • [15] The Effect of Adding Pertuzumab to Adjuvant Trastuzumab in Early HER2-Positive Breast Cancer
    Al-Azawi, Ahmed
    Hneua, Riyadh Abd-Alrasool
    Hameed, Rana Majeed
    Hassan, Duha Maithem
    JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2023, 9 (03): : 197 - 200
  • [16] Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients
    Mustacchi, G.
    Puglisi, F.
    Molino, A. M.
    Crivellari, D.
    Ghiotto, C.
    Ferro, A.
    Brunello, A.
    Saracchini, S.
    Turazza, M.
    Cretella, E.
    Iop, A.
    Malagoli, M.
    Stefani, M.
    FUTURE ONCOLOGY, 2015, 11 (10) : 1493 - 1500
  • [17] EVALUATION OF TRASTUZUMAB FOR ADJUVANT THERAPY OF HER2-POSITIVE BREAST CANCER EGYPTIAN FEMALES
    Abbas, N. A. R.
    ANNALS OF ONCOLOGY, 2010, 21 : 44 - 44
  • [18] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Yamshiro, Hiroyasu
    Iwata, Hiroji
    Masuda, Norikazu
    Yamamoto, Naohito
    Nishimura, Reiki
    Ohtani, Shoichiro
    Sato, Nobuki
    Takahashi, Masato
    Kamio, Takako
    Yamazaki, Kosuke
    Saito, Tsuyoshi
    Kato, Makoto
    Lee, Tecchuu
    Ohno, Shinji
    Kuroi, Katsumasa
    Takano, Toshimi
    Takada, Masahiro
    Yasuno, Shinji
    Morita, Satoshi
    Toi, Masakazu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (04) : 709 - 722
  • [19] Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients
    Hiroyasu Yamshiro
    Hiroji Iwata
    Norikazu Masuda
    Naohito Yamamoto
    Reiki Nishimura
    Shoichiro Ohtani
    Nobuki Sato
    Masato Takahashi
    Takako Kamio
    Kosuke Yamazaki
    Tsuyoshi Saito
    Makoto Kato
    Tecchuu Lee
    Shinji Ohno
    Katsumasa Kuroi
    Toshimi Takano
    Masahiro Takada
    Shinji Yasuno
    Satoshi Morita
    Masakazu Toi
    International Journal of Clinical Oncology, 2015, 20 : 709 - 722
  • [20] Trastuzumab use at relapse after adjuvant trastuzumab therapy in HER2-positive breast cancer.
    Lang, I.
    Bell, R.
    Feng, F.
    Lopez, R. I.
    Jassem, J.
    Semiglazov, V.
    Al-Sakaff, N.
    Carreras, E.
    Chang, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345